NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing nanomedicines for antiviral therapy, announced that it will present at the NIBA 153rd Investment Conference on Oct. 7, 2026, in Fort Lauderdale, Florida. The presentation comes as the company advances NV-387, its lead broad-spectrum antiviral candidate, which is currently in separate Phase 2 clinical trials in the Democratic Republic of Congo for Ebola Bundibugyo virus disease and Mpox. These trials represent a critical step for a drug that could address multiple high-consequence viral pathogens with a single therapeutic approach.
The significance of NanoViricides' work lies in its potential to overcome the limitations of traditional antiviral drugs, which are typically virus-specific. NV-387 is designed to target a broad range of viruses by mimicking the host cell receptors that viruses attach to, thereby neutralising them. If successful, this platform could provide a rapid response option for emerging viral outbreaks, where developing a new drug from scratch is often too slow. The ongoing Ebola and Mpox trials are particularly noteworthy because they test the drug in real-world outbreak settings, where need is urgent and treatment options are limited.
Beyond these indications, NanoViricides is planning clinical trials of NV-387 for measles, for which the drug has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA). These designations are intended to incentivise development of treatments for rare diseases and could expedite the review process. The company is also pursuing trials for viral acute respiratory infections, a broad category that includes influenza, RSV, and COVID-19. This expansion into respiratory viruses could position NV-387 as a versatile tool against seasonal and pandemic threats.
The company's pipeline includes additional candidates: NV-HHV-1 for herpesviridae viruses and NV-HIV-1 for HIV/AIDS. This diverse portfolio underscores NanoViricides' strategy of leveraging its nanoviricide platform to tackle multiple viral families. For investors, the upcoming NIBA conference provides an opportunity to assess the company's progress and strategic direction. More details are available in the full press release at https://ibn.fm/vQCM4.
NanoViricides' business model is based on licensing technology from TheraCour Pharma, Inc., and it holds broad exclusive licenses for several antiviral fields. The company's lead drug, NV-387, is also being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. The company's other advanced candidate, NV-HHV-1, targets shingles. While the path to regulatory approval is lengthy and capital-intensive, the company's focus on broad-spectrum antivirals could offer a differentiated approach in a market where few options exist for many viral diseases.
InvestorWire, a specialized communications platform, distributes news for NanoViricides and other companies. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For full terms of use and disclaimers, visit https://www.InvestorWire.com/Disclaimer.
